% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wurschi:305349,
author = {G. Wurschi and M. Kesselmeier and M. Schneider and J.-N.
Becker and B. Frerker and S. M. Vorbach and F. Ehret$^*$ and
M. Diefenhardt and F. Schunn and M.-E. von Gruben and M.
Büttner$^*$ and E. Hoffmann$^*$ and A. Rühle$^*$ and J.
Beier and S. Ferdinandus and M. Trommer and E. C. Sahin and
J. Hlouschek and K. Aninditha and D. S. von Ohlen and J.
Kaufmann and A. Depardon and H. M. Ha and S. Trommer and C.
Kessler and A. Cieslak and A. Fabian and F. Rißner and M.
Römer and M. Mäurer and K. Pietschmann},
title = {{S}hort-course radiotherapy versus long-course
chemoradiotherapy in total neoadjuvant therapy of rectal
cancer - {A} multicenter analysis of early outcomes and
toxicity.},
journal = {Radiotherapy and oncology},
volume = {213},
issn = {0167-8140},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DKFZ-2025-02093},
pages = {111194},
year = {2025},
note = {2025 Dec;213:111194},
abstract = {Total neoadjuvant therapy (TNT) improves local control and
complete response (CR) rates in locally advanced rectal
cancer (LARC). CR is associated with favorable local tumor
control, allowing non-operative management (NOM). However,
it remains unclear whether short-course radiotherapy (SCRT)
or long-course chemoradiotherapy (LCRT) is preferable within
TNT.LARC patients undergoing TNT between 2015 and 2024 were
included in this retrospective multicenter analysis
(DRKS00033000). The primary endpoint was CR. Secondary
endpoints comprised NOM rates, toxicity, and tumor control.
Multivariable logistic regression modelling was used to
assess the influence of LCRT.Of 295 included patients with a
median age at diagnosis of 62 (Q1-Q3: 54-68) years and 210
(71.2 $\%)$ men, 172 (58.3 $\%)$ underwent LCRT. CR was
achieved in 46 (37.4 $\%)$ SCRT and 96 (55.8 $\%)$ LCRT
patients. Acute toxicity grade ≥ 3 occurred in 24 (20.5
$\%)$ of 117 SCRT and in 62 (36.3 $\%)$ of 171 LCRT
patients. Within a median follow-up of 19.4 months (SCRT)
and 19.6 months (LCRT), 23 (19.8 $\%)$ of 116 and 30 (19.4
$\%)$ of 155 patients experienced recurrence, respectively.
Regression modelling revealed an increased likelihood for CR
(adjusted odds ratio: 3.11; 95 $\%$ confidence interval:
1.37-7.07) and NOM (4.40; 1.46-13.21) with LCRT, whereas no
significant associations of LCRT with acute toxicity (0.90;
0.40-2.02), chronic toxicity (1.16; 0.48-2.78),
postoperative complications (0.89; 0.62-1.28) or recurrence
(0.81; 0.31-2.16) were observed.LCRT was associated with
higher CR and NOM rates. Whether it might be preferred over
SCRT for intended NOM remains a relevant question to be
answered by ongoing randomized trials.},
keywords = {Chemoradiotherapy (Other) / Complete response (Other) /
Rectal cancer (Other) / Total neoadjuvant therapy (Other)},
cin = {BE01 / TU01 / FR01},
ddc = {610},
cid = {I:(DE-He78)BE01-20160331 / I:(DE-He78)TU01-20160331 /
I:(DE-He78)FR01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:41077142},
doi = {10.1016/j.radonc.2025.111194},
url = {https://inrepo02.dkfz.de/record/305349},
}